1. Six more biotechs price public debuts just before the start of the weekend—Surprise pandemic lessons for pharma -- August FDA decisions for Axsome, Sanofi, Merck See more on our front page news
    Dismiss Notice
  2. Do you have general questions about dealing with sexual harassment or discrimination at work? Ask an attorney on this forum.
    Dismiss Notice

Doesn’t look good for IM...

Discussion in 'Pfizer' started by anonymous, Jun 1, 2021 at 10:53 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Reyvow contract no more after June... Unbelievable how quickly things went from looking great to terrible. Is there even going to be any full time IM sales representative positions under Bold Moves 3.3?
     

  2. anonymous

    anonymous Guest

    Who has been selling Reyvow? I've never heard of it...but I'm not in IM either.
     
  3. anonymous

    anonymous Guest

    Team 1 TM’s and STM’s. Just when you think it couldn’t get any worse!
     
  4. anonymous

    anonymous Guest

    IM has Eliquis. not much more
     
  5. anonymous

    anonymous Guest

    40% split on Eliquis is only profitable IM model.
    IM will be thing of past after Eliquis LOEs
     
  6. anonymous

    anonymous Guest

    I think Team 1 will be eliminated completely.
     
  7. anonymous

    anonymous Guest

    get rid of all reps
     
  8. anonymous

    anonymous Guest

    Yup, the party is over folks!
     
  9. anonymous

    anonymous Guest

    Someone who views this forum has to have some insight. Give us some info
     
  10. anonymous

    anonymous Guest

    Elliquois reps probably have the best chance of staying but there will still be less of them. Geographies will grow significantly. I don’t know if they’ll keep any team 1 reps or get rid of all of them. You still have a Cologuard contract butI guess you could fulfill that will inside sales reps.
     
  11. anonymous

    anonymous Guest

    Whatever happens, I think it will be sooner than we think. Team 1 STM’s have been told they will start to sample Premarin in July but yet they have not received any training on it. Team 2 still has no elliquois samples. Reyvow contract ends. Nobody really seems to care about Cologuard contract.
     
  12. anonymous

    anonymous Guest

    To be honest, Pfizer could possibly buy its way out of the Cologuard contract. The financial analysts could determine if that route would be less costly that retaining headcount to continue it.
     
  13. anonymous

    anonymous Guest

    It was always interesting to me that the Eliquis reps had huge geographic areas compared to Team 1 and Eliquis was so much more successful than Team 1 products.
     
  14. anonymous

    anonymous Guest

    Not true in my area. Our Elliquois rep has a small territory.
     
  15. anonymous

    anonymous Guest

    how much revenue does Cologuard bring into the company?
     
  16. anonymous

    anonymous Guest

    I’m an Eliquis rep and our territories are drawn to be at least 3 times larger than the other team. Your Eliquis rep may have narrowed down his accounts , but geographically, it is large.Or the accounts have huge potential.
     
  17. anonymous

    anonymous Guest

    It’s Eliquis dipshit
     
  18. anonymous

    anonymous Guest

    someone reading this forum is desperate to try and get their stock price to move up and so just keeps the same idea about eliminating reps. as if that will help rofl
     
  19. anonymous

    anonymous Guest

    Just lay me off already. The waiting game is brutal.
     
  20. anonymous

    anonymous Guest

    Did anyone else really look at that model presented in the last call? The only reps listed on there were inside sales reps.